Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives

Srinivas Deekonda, Lauren Wugalter, David Rankin, Tally M. Largent-Milnes, Peg Davis, Yue Wang, Neemah M. Bassirirad, Josephine Lai, Vinod Kulkarni, Todd W Vanderah, Frank Porreca, Victor J Hruby

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We describe the design and synthesis of novel bivalent ligands based on the conjugation of 4-anilidopiperidine derivatives with enkephalin analogues. The design of non-peptide analogues is explored with 5-amino substituted (tetrahydronaphthalen-2yl) methyl containing 4-anilidopiperidine derivatives, while non-peptide-peptide ligands are explored by conjugating the C-terminus of enkephalin analogues (H-Xxx-DAla-Gly-Phe-OH) to the amino group of 4-anilidopiperidine small molecule derivatives with and without a linker. These novel bivalent ligands are evaluated for biological activities at μ and δ opioid receptors. They exhibit very good affinities at μ and δ opioid receptors, and potent agonist activities in MVD and GPI assays. Among these the lead bivalent ligand 17 showed excellent binding affinities (0.1 nM and 0.5 nM) at μ and δ opioid receptors respectively, and was found to have very potent agonist activities in MVD (56 ± 5.9 nM) and GPI (4.6 ± 1.9 nM) assays. In vivo the lead bivalent ligand 17 exhibited a short duration of action (

Original languageEnglish (US)
Pages (from-to)4683-4688
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume25
Issue number20
DOIs
StatePublished - May 28 2015

Fingerprint

Enkephalins
Ligands
Derivatives
Opioid Receptors
Assays
glycylphenylalanine
Bioactivity
4-anilidopiperidine
Peptides
Molecules
Lead

Keywords

  • Bivalent ligands
  • Enkephalins
  • Opioid receptors
  • Opioids

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. / Deekonda, Srinivas; Wugalter, Lauren; Rankin, David; Largent-Milnes, Tally M.; Davis, Peg; Wang, Yue; Bassirirad, Neemah M.; Lai, Josephine; Kulkarni, Vinod; Vanderah, Todd W; Porreca, Frank; Hruby, Victor J.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 25, No. 20, 28.05.2015, p. 4683-4688.

Research output: Contribution to journalArticle

Deekonda, Srinivas ; Wugalter, Lauren ; Rankin, David ; Largent-Milnes, Tally M. ; Davis, Peg ; Wang, Yue ; Bassirirad, Neemah M. ; Lai, Josephine ; Kulkarni, Vinod ; Vanderah, Todd W ; Porreca, Frank ; Hruby, Victor J. / Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. In: Bioorganic and Medicinal Chemistry Letters. 2015 ; Vol. 25, No. 20. pp. 4683-4688.
@article{5d78dd2b38a54aeca9d47a22c0357c6d,
title = "Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives",
abstract = "We describe the design and synthesis of novel bivalent ligands based on the conjugation of 4-anilidopiperidine derivatives with enkephalin analogues. The design of non-peptide analogues is explored with 5-amino substituted (tetrahydronaphthalen-2yl) methyl containing 4-anilidopiperidine derivatives, while non-peptide-peptide ligands are explored by conjugating the C-terminus of enkephalin analogues (H-Xxx-DAla-Gly-Phe-OH) to the amino group of 4-anilidopiperidine small molecule derivatives with and without a linker. These novel bivalent ligands are evaluated for biological activities at μ and δ opioid receptors. They exhibit very good affinities at μ and δ opioid receptors, and potent agonist activities in MVD and GPI assays. Among these the lead bivalent ligand 17 showed excellent binding affinities (0.1 nM and 0.5 nM) at μ and δ opioid receptors respectively, and was found to have very potent agonist activities in MVD (56 ± 5.9 nM) and GPI (4.6 ± 1.9 nM) assays. In vivo the lead bivalent ligand 17 exhibited a short duration of action (",
keywords = "Bivalent ligands, Enkephalins, Opioid receptors, Opioids",
author = "Srinivas Deekonda and Lauren Wugalter and David Rankin and Largent-Milnes, {Tally M.} and Peg Davis and Yue Wang and Bassirirad, {Neemah M.} and Josephine Lai and Vinod Kulkarni and Vanderah, {Todd W} and Frank Porreca and Hruby, {Victor J}",
year = "2015",
month = "5",
day = "28",
doi = "10.1016/j.bmcl.2015.07.064",
language = "English (US)",
volume = "25",
pages = "4683--4688",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "20",

}

TY - JOUR

T1 - Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives

AU - Deekonda, Srinivas

AU - Wugalter, Lauren

AU - Rankin, David

AU - Largent-Milnes, Tally M.

AU - Davis, Peg

AU - Wang, Yue

AU - Bassirirad, Neemah M.

AU - Lai, Josephine

AU - Kulkarni, Vinod

AU - Vanderah, Todd W

AU - Porreca, Frank

AU - Hruby, Victor J

PY - 2015/5/28

Y1 - 2015/5/28

N2 - We describe the design and synthesis of novel bivalent ligands based on the conjugation of 4-anilidopiperidine derivatives with enkephalin analogues. The design of non-peptide analogues is explored with 5-amino substituted (tetrahydronaphthalen-2yl) methyl containing 4-anilidopiperidine derivatives, while non-peptide-peptide ligands are explored by conjugating the C-terminus of enkephalin analogues (H-Xxx-DAla-Gly-Phe-OH) to the amino group of 4-anilidopiperidine small molecule derivatives with and without a linker. These novel bivalent ligands are evaluated for biological activities at μ and δ opioid receptors. They exhibit very good affinities at μ and δ opioid receptors, and potent agonist activities in MVD and GPI assays. Among these the lead bivalent ligand 17 showed excellent binding affinities (0.1 nM and 0.5 nM) at μ and δ opioid receptors respectively, and was found to have very potent agonist activities in MVD (56 ± 5.9 nM) and GPI (4.6 ± 1.9 nM) assays. In vivo the lead bivalent ligand 17 exhibited a short duration of action (

AB - We describe the design and synthesis of novel bivalent ligands based on the conjugation of 4-anilidopiperidine derivatives with enkephalin analogues. The design of non-peptide analogues is explored with 5-amino substituted (tetrahydronaphthalen-2yl) methyl containing 4-anilidopiperidine derivatives, while non-peptide-peptide ligands are explored by conjugating the C-terminus of enkephalin analogues (H-Xxx-DAla-Gly-Phe-OH) to the amino group of 4-anilidopiperidine small molecule derivatives with and without a linker. These novel bivalent ligands are evaluated for biological activities at μ and δ opioid receptors. They exhibit very good affinities at μ and δ opioid receptors, and potent agonist activities in MVD and GPI assays. Among these the lead bivalent ligand 17 showed excellent binding affinities (0.1 nM and 0.5 nM) at μ and δ opioid receptors respectively, and was found to have very potent agonist activities in MVD (56 ± 5.9 nM) and GPI (4.6 ± 1.9 nM) assays. In vivo the lead bivalent ligand 17 exhibited a short duration of action (

KW - Bivalent ligands

KW - Enkephalins

KW - Opioid receptors

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=84942982043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942982043&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2015.07.064

DO - 10.1016/j.bmcl.2015.07.064

M3 - Article

VL - 25

SP - 4683

EP - 4688

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 20

ER -